NERV Minerva Neurosciences Inc

5.57
-0.36  -6%
Previous Close 5.93
Open 5.71
Price To Book 2.81
Market Cap 217,371,873
Shares 39,025,471
Volume 2,726,595
Short Ratio
Av. Daily Volume 767,036

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 3Q 2019.
MIN-202 (seltorexant) vs quetiapine
Major Depressive Disorder
Phase 2b data May 13, 2019 noted p-value was 0.083.
MIN-202 (seltorexant)
Major Depressive Disorder
Phase 2b data due 4Q 2019.
MIN-117
Major Depressive Disorder
Phase 3 data due 4Q 2019.
Roluperidone (MIN-101)
Schizophrenia
Phase 2b data June 24, 2019 met primary endpoint.
MIN-202 (seltorexant)
Primary insomnia

Latest News

  1. Minerva Spikes Higher After Novel Insomnia Drug Aces Mid-Stage Trial
  2. UPDATE: Minerva Neurosciences stock rallies after trial of insomnia treatment meets main goals
  3. Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia
  4. Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant
  5. Minerva Neurosciences to Present at JMP Securities Life Sciences Conference
  6. Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019
  7. Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug
  8. Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs
  9. Edited Transcript of NERV earnings conference call or presentation 6-May-19 12:30pm GMT
  10. Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)
  11. Minerva Neurosciences, Inc. (NERV) Q1 2019 Earnings Call Transcript
  12. Minerva Neurosciences: 1Q Earnings Snapshot
  13. Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates
  14. Minerva Neurosciences to Report First Quarter 2019 Financial Results and Business Updates on May 6, 2019
  15. Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
  16. Edited Transcript of NERV earnings conference call or presentation 12-Mar-19 12:30pm GMT
  17. Minerva Neurosciences to Host Webcast Event on Schizophrenia
  18. Minerva Neurosciences Inc (NERV) Q4 2018 Earnings Conference Call Transcript
  19. Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates